SCHEMBL4286733

SCHEMBL4286733

CC(=O)N1CCN(c2ccc(OCC[C@@H]3CN(C(=O)O)CCN3C(=O)O)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.49
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
USP2 O75604 1/20 0.49
HIF1A Q16665 1/20 0.49
KDM1A O60341 2/20 0.47
GAA P10253 3/20 0.46
KDM4E B2RXH2 2/20 0.45
NPC1 O15118 2/20 0.45
GFER P55789 2/20 0.43
CASP6 P55212 1/20 0.43
LMNA P02545 2/20 0.43
DRD3 P35462 1/20 0.43
MAPK1 P28482 4/20 0.42
RAB9A P51151 1/20 0.42
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4294542 0.84 KDM4E (0.49) MAPTALDH1A1GAAKDM4ENPC1
SCHEMBL4281983 0.84 L3MBTL1 (0.48) MAPTALDH1A1SMN1; SMN2GAAKDM4E
SCHEMBL4286026 0.84 HPGD (0.49) MAPTALDH1A1SMN1; SMN2GAAKDM4E
SCHEMBL4298298 0.84 KDM4E (0.46) MAPTALDH1A1GAAKDM4EMAPK1
SCHEMBL3494366 0.82 TEAD1 (0.50) MAPTALDH1A1SMN1; SMN2USP2GAA
SCHEMBL4286428 0.82 HCRTR1 (0.47) MAPTALDH1A1SMN1; SMN2GAAKDM4E
SCHEMBL4281940 0.82 KCNA5 (0.46) ALDH1A1LMNARAB9AMEN1KMT2A
SCHEMBL4287459 0.81 KMT2A (0.49) ALDH1A1SMN1; SMN2GAAKDM4ENPC1
SCHEMBL4295216 0.81 KMT2A (0.49) MAPTALDH1A1KDM4ENPC1RAB9A
SCHEMBL4285825 0.81 KCNA5 (0.49) MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT MAPT 3142/4885ALDH1A1 388/4885SMN1; SMN2 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.